NetScientific PLC: Life Sciences & Technology Investments

Backing Ambition, Investing in Execution

ABOUT US

thisisengineering-raeng-qI7USKbZY_A-unsplash

Leveraging Trans-Atlantic Relationships & Global Opportunities

OUR TEAM

Investment and Technology Commercialisation in Life Sciences, Technology and Sustainability

PORTFOLIO

Customized Investment Strategy for Each Portfolio Company

LEARN MORE

NetScientific PLC is a life sciences and sustainability technology investment and commercialisation group
We leverage trans-Atlantic relationships and global opportunities to deliver shareholder value.

We look to maximise shareholder returns through focused execution of our investment strategy with current portfolio companies, and targeted investments in existing and new investment opportunities.

NetScientific develops a customized investment and realisation strategy for its portfolio companies.
We seek to enable the companies we work to access the right type of funding, proactive management support and resources specific to their sector, stage of development and available opportunities.

NetScientific is a holding company of its various technology businesses. It is not an AIM Investing Company

Our Subsidiaries and Portfolio

A Focus on Life Sciences, Technology, and Sustainability

See our Portfolio

Board and Management

Sector-specialist senior management team with extensive commercial experience.

Dr Ilian Iliev

Chief Executive Officer

John Clarkson

Executive Chairman

Clive Sparrow

Non-Executive Director

Professor Stephen Smith

Non-Executive Director

Stephen Crowe

Chief Financial Officer

See our Team

News

PDS Biotech Announces Mount Sinai Publication of Studies Showing Superior Induction of Antibodies by Versamune®-based COVID-19 Vaccine

Dec 21, 2020

News, PDS Biotechnology, RNS Announcements

NetScientific plc ("NetScientific" or the "Company") PDS Biotech Announces Mount Sinai Publication of Studies Showing Superior Induction of Antibodies by Versamune®-based COVID-19 Vaccine Versamune® T-cell activating platform demonstrates breadth of anti-SARS-CoV-2 immune responses in a COVID-19 vaccine London, UK – 21 December 2020 – NetScientific plc (AIM: NSCI), the life sciences, technology, investment and commercialisation company, [...]

6 MIN READ

ProAxsis Limited awarded Innovate UK grant to utilise company technology to identify high risk COVID-19 patients

Dec 10, 2020

News, ProAxsis, RNS Announcements

NetScientific plc ("NetScientific" or the "Company") ProAxsis Limited awarded Innovate UK grant to utilise company technology to identify high risk COVID-19 patients London, UK - 10 December 2020 - NetScientific plc (AIM: NSCI), the life sciences, technology, investment and commercialisation company, announces that its portfolio company ProAxsis Limited ("ProAxsis"), announced that it has been awarded [...]